🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China flag China · Delayed Price · Currency is CNY
23.27
-0.26 (-1.11%)
Nov 18, 2026, 4:00 PM EST

SHA:603235 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
2,5562,3222,1811,8512,2532,466
Other Revenue
22.7422.742830.651.7155.97
2,5792,3452,2091,8822,3052,522
Revenue Growth
15.87%6.18%17.35%-18.34%-8.63%9.50%
Cost of Revenue
1,5581,3691,2881,1741,4501,432
Gross Profit
1,021975.8920.91708.11854.671,090
Selling, General & Admin
231.8218.12177.02169.21174.88140.19
Research & Development
129.75100.52103.82111.9689.4658.94
Other Operating Expenses
34.7624.4417.8619.8121.9722.77
Operating Expenses
397.17343.35301.92299.32282.46228.3
Operating Income
624.19632.45619408.79572.21862.11
Interest Expense
--0.47-2.48-2.1-6.93-12.67
Interest & Investment Income
49.6146.3264.8176.5422.884.34
Currency Exchange Gain (Loss)
-10.52-10.5254.1931.2482.37-26.95
Other Non Operating Income (Expenses)
-53.8-1.26-1.250.32-1.74-1.61
EBT Excluding Unusual Items
609.49666.52734.26514.79668.79825.22
Gain (Loss) on Sale of Investments
-0.47-2.24-4.33-6.61
Gain (Loss) on Sale of Assets
-1.69-1.49-1.07-0.09-1.07-2.14
Asset Writedown
7.99-0.92-0.61-0.19-0.86-
Other Unusual Items
40.1140.3136.9550.6654.5756.91
Pretax Income
655.43704.42771.77565.17725.76873.37
Income Tax Expense
103.89112.84120.5589.32103.64129.49
Net Income
551.54591.58651.22475.85622.12743.89
Net Income to Common
551.54591.58651.22475.85622.12743.89
Net Income Growth
-10.62%-9.16%36.85%-23.51%-16.37%-16.14%
Shares Outstanding (Basic)
437438437437412394
Shares Outstanding (Diluted)
437438437437412394
Shares Change
0.67%0.26%0.11%5.96%4.68%-0.10%
EPS (Basic)
1.261.351.491.091.511.89
EPS (Diluted)
1.261.351.491.091.511.89
EPS Growth
-11.21%-9.40%36.70%-27.82%-20.11%-16.00%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
381.4448.68-567.3193.61346.11603.13
Free Cash Flow Per Share
0.870.11-1.300.440.841.53
Dividend Per Share
0.5500.5500.6800.5000.710-
Dividend Growth
-19.12%-19.12%36.00%-29.58%--
Gross Margin
39.60%41.61%41.70%37.63%37.08%43.23%
Operating Margin
24.20%26.97%28.03%21.72%24.83%34.18%
Profit Margin
21.38%25.23%29.49%25.29%26.99%29.49%
Free Cash Flow Margin
14.79%2.08%-25.69%10.29%15.02%23.91%
EBITDA
836.38818.53770.25544.64695.81969.57
EBITDA Margin
32.43%34.91%34.88%28.94%30.19%38.44%
D&A For EBITDA
212.19186.08151.25135.85123.6107.46
EBIT
624.19632.45619408.79572.21862.11
EBIT Margin
24.20%26.97%28.03%21.72%24.83%34.18%
Effective Tax Rate
15.85%16.02%15.62%15.80%14.28%14.83%
Revenue as Reported
2,5792,3452,2091,8822,3052,522